Page last updated: 2024-12-06

2',5'-dideoxyadenosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2',5'-dideoxyadenosine, also known as ddA, is a nucleoside analog that is a potent inhibitor of HIV-1 reverse transcriptase. It was first synthesized in 1976 and has been studied extensively for its antiviral properties. ddA has been shown to be effective in vitro and in vivo against HIV-1, and it is currently used in combination therapy for the treatment of AIDS. ddA inhibits DNA synthesis by acting as a chain terminator, preventing the addition of further nucleotides to the growing DNA chain. ddA is also a substrate for adenosine deaminase, which converts it to 2',5'-dideoxyinosine (ddI), another potent anti-HIV drug. ddA is generally well tolerated, but it can cause side effects such as peripheral neuropathy, pancreatitis, and lactic acidosis. ddA is a valuable tool for studying the mechanism of HIV-1 replication and for developing new anti-HIV drugs.'

Cross-References

ID SourceID
PubMed CID65166
CHEMBL ID1253350
CHEBI ID195578
SCHEMBL ID284737
MeSH IDM0075411

Synonyms (27)

Synonym
6698-26-6
2',5'-dideoxyadenosine, >=95% (hplc), solid
2',5-dideoxyadenosine
(2r,3s,5r)-5-(6-aminopurin-9-yl)-2-methyloxolan-3-ol
2',5'-dideoxyadenosine
CHEBI:195578
adenosine, 2',5'-dideoxy-
988h339z1l ,
nsc 95943
unii-988h339z1l
CHEMBL1253350
2'5'-dideoxyadenosine
AKOS016003707
gtpl5108
(2r,3s,5r)-5-(6-amino-9h-purin-9-yl)-2-methyloxolan-3-ol
SCHEMBL284737
FFHPXOJTVQDVMO-DSYKOEDSSA-N
adenosine,2',5'-dideoxy-
(2r,3s,5r)-5-(6-amino-9h-purin-9-yl)-2-methyltetrahydrofuran-3-ol
NCGC00485002-01
2',5'-dideoxyadenosine - cas 6698-26-6
E75785
Q27071874
CS-0115920
HY-135878
AS-77458
PD041233

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
deoxyribonucleoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID514293Induction of autophagy in african green monkey COS7 cells expressing EGFP-HDQ74/m-calpain assessed as decrease in EGFP-HDQ74 aggregation at 500 uM after 48 hrs2008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
AID513642Induction of autophagy in rat stable inducible PC12 cells assessed as increase in LC3-2 level at 500 uM after 24 hrs by immunoblotting analysis2008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
AID514307Protection of neurodegeneration in zebrafish Huntington's disease model expressing EGFP-tagged huntingtin exon with EGFP-HDQ71 in rod photoreceptor assessed as induction of rhodopsin expression at 100 uM2008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
AID514305Protection of neurodegeneration in zebrafish Huntington's disease model expressing EGFP-tagged huntingtin exon with EGFP-HDQ71 in rod photoreceptor assessed as decrease in EGFP-HDQ74 aggregation at 100 uM2008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
AID513640Induction of autophagy in rat stable inducible PC12 cells expressing A53T alpha-synuclein assessed as A53T alpha-synuclein clearance at 500 uM after 24 hrs by densitometric analysis2008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
AID513641Induction of autophagy in human SK-N-SH cells expressing EGFP-HDQ74 assessed as reduction in EGFP-HDQ74 aggregation at 500 uM after 48 hrs by densitometric analysis2008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
AID514291Induction of autophagy in rat stable inducible PC12 cells expressing A53T alpha-synuclein assessed as inhibition of PACAP-retarded A53T alpha-synuclein clearance at 500 uM after 24 hrs by densitometric analysis2008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (123)

TimeframeStudies, This Drug (%)All Drugs %
pre-199059 (47.97)18.7374
1990's27 (21.95)18.2507
2000's25 (20.33)29.6817
2010's9 (7.32)24.3611
2020's3 (2.44)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.04 (24.57)
Research Supply Index4.83 (2.92)
Research Growth Index4.23 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (0.81%)4.05%
Observational0 (0.00%)0.25%
Other123 (99.19%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]